PASW
Ping An Biomedical Co., Ltd. (PASW) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Current ratio of 2.76 and quick ratio of 2.74 indicate liquidity above many peers, supporting near-term resilience despite weaker operating performance.
Debt-to-equity of 0.23 suggests a relatively conservative capital structure versus more levered peers, limiting refinancing pressure and balance-sheet risk.
Net debt to EBITDA is negative at -0.65, implying net cash rather than net leverage, which is structurally stronger than indebted peers.
The company’s cash conversion cycle of 85.7 days is manageable for a working-capital business, though it remains less efficient than faster-turning peers.
Weaknesses
Return on invested capital of -23.1% signals value destruction and materially trails profitable peers, indicating the business is not yet converting capital into returns.
The 85.7-day cash conversion cycle ties up cash for longer than efficient peers, which weakens operating flexibility and depresses reinvestment capacity.
Missing margin disclosure alongside weak returns suggests limited evidence of durable pricing power versus peers, constraining confidence in structural profitability.
Despite a strong liquidity profile, the absence of positive operating returns leaves the company structurally weaker than peers with proven earnings quality.
Opportunities
If working-capital discipline improves, the 85.7-day cash conversion cycle could narrow versus peers and release cash for growth or deleveraging.
The net cash position provides optionality to fund operational improvements faster than more leveraged peers, supporting a potential relative repositioning.
With current and quick ratios both above 2.7, management has room to absorb execution costs while pursuing efficiency gains that peers with tighter liquidity cannot.
Any future margin expansion would have an outsized effect from the current low base, allowing the company to close the gap with stronger peers.
Threats
Persistently negative ROIC increases the risk that peers with positive returns compound faster, widening the competitive gap over the next several years.
A long cash conversion cycle can leave the company exposed to working-capital shocks, while faster-turning peers preserve more operating flexibility.
If liquidity is used to offset ongoing operating losses, the current balance-sheet cushion could erode faster than peers with sustainable earnings.
Without visible margin data or segment diversification evidence, peers with clearer profitability and scale advantages may continue to outcompete the business.
Overall Score
PASW shows balance-sheet liquidity and low leverage, but deeply negative returns on capital and slow cash conversion leave it structurally behind stronger peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Ping An Biomedical Co., Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
